BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 22112818)

  • 1. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients.
    Utz JR; Lorentz CP; Markowitz D; Rudser KD; Diethelm-Okita B; Erickson D; Whitley CB
    Mol Genet Metab; 2012 Feb; 105(2):193-7. PubMed ID: 22112818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias.
    Blau N
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1207-18. PubMed ID: 23705856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unresponsiveness to tetrahydrobiopterin of phenylalanine hydroxylase deficiency.
    Ponzone A; Porta F; Mussa A; Alluto A; Ferraris S; Spada M
    Metabolism; 2010 May; 59(5):645-52. PubMed ID: 19913839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study.
    Keil S; Anjema K; van Spronsen FJ; Lambruschini N; Burlina A; Bélanger-Quintana A; Couce ML; Feillet F; Cerone R; Lotz-Havla AS; Muntau AC; Bosch AM; Meli CA; Billette de Villemeur T; Kern I; Riva E; Giovannini M; Damaj L; Leuzzi V; Blau N
    Pediatrics; 2013 Jun; 131(6):e1881-8. PubMed ID: 23690520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria.
    Heintz C; Cotton RG; Blau N
    Hum Mutat; 2013 Jul; 34(7):927-36. PubMed ID: 23559577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of patients with phenylketonuria in the US to tetrahydrobiopterin.
    Matalon R; Michals-Matalon K; Koch R; Grady J; Tyring S; Stevens RC
    Mol Genet Metab; 2005 Dec; 86 Suppl 1():S17-21. PubMed ID: 16143554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency.
    Karacić I; Meili D; Sarnavka V; Heintz C; Thöny B; Ramadza DP; Fumić K; Mardesić D; Barić I; Blau N
    Mol Genet Metab; 2009 Jul; 97(3):165-71. PubMed ID: 19394257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylalanine hydroxylase genotype-phenotype associations in the United States: A single center study.
    Rajabi F; Rohr F; Wessel A; Martell L; Dobrowolski SF; Guldberg P; Güttler F; Levy HL
    Mol Genet Metab; 2019 Dec; 128(4):415-421. PubMed ID: 31623983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics and impact of residual in vitro phenylalanine hydroxylase activity on tetrahydrobiopterin responsiveness in Turkish PKU population.
    Dobrowolski SF; Heintz C; Miller T; Ellingson C; Ellingson C; Ozer I; Gökçay G; Baykal T; Thöny B; Demirkol M; Blau N
    Mol Genet Metab; 2011 Feb; 102(2):116-21. PubMed ID: 21147011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria.
    Muntau AC; Röschinger W; Habich M; Demmelmair H; Hoffmann B; Sommerhoff CP; Roscher AA
    N Engl J Med; 2002 Dec; 347(26):2122-32. PubMed ID: 12501224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.
    Trefz FK; Burton BK; Longo N; Casanova MM; Gruskin DJ; Dorenbaum A; Kakkis ED; Crombez EA; Grange DK; Harmatz P; Lipson MH; Milanowski A; Randolph LM; Vockley J; Whitley CB; Wolff JA; Bebchuk J; Christ-Schmidt H; Hennermann JB;
    J Pediatr; 2009 May; 154(5):700-7. PubMed ID: 19261295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of BH4-responsiveness in phenylalanine-hydroxylase-deficient Italian patients.
    Fiori L; Fiege B; Riva E; Giovannini M
    Mol Genet Metab; 2005 Dec; 86 Suppl 1():S67-74. PubMed ID: 16198137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
    Sanford M; Keating GM
    Drugs; 2009; 69(4):461-76. PubMed ID: 19323589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Characterization of Novel Phenylalanine Hydroxylase p.Gln226Lys Mutation Revealed Its Non-responsiveness to Tetrahydrobiopterin Treatment in Hepatoma Cellular Model.
    Klaassen K; Djordjevic M; Skakic A; Desviat LR; Pavlovic S; Perez B; Stojiljkovic M
    Biochem Genet; 2018 Oct; 56(5):533-541. PubMed ID: 29654578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenylalanine hydroxylase deficiency in the Slovak population: genotype-phenotype correlations and genotype-based predictions of BH4-responsiveness.
    Polak E; Ficek A; Radvanszky J; Soltysova A; Urge O; Cmelova E; Kantarska D; Kadasi L
    Gene; 2013 Sep; 526(2):347-55. PubMed ID: 23764561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
    Burton BK; Nowacka M; Hennermann JB; Lipson M; Grange DK; Chakrapani A; Trefz F; Dorenbaum A; Imperiale M; Kim SS; Fernhoff PM
    Mol Genet Metab; 2011 Aug; 103(4):315-22. PubMed ID: 21646032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A limited spectrum of phenylalanine hydroxylase mutations is observed in phenylketonuria patients in western Poland and implications for treatment with 6R tetrahydrobiopterin.
    Dobrowolski SF; Borski K; Ellingson CC; Koch R; Levy HL; Naylor EW
    J Hum Genet; 2009 Jun; 54(6):335-9. PubMed ID: 19444284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria.
    Muntau AC; Adams DJ; Bélanger-Quintana A; Bushueva TV; Cerone R; Chien YH; Chiesa A; Coşkun T; de Las Heras J; Feillet F; Katz R; Lagler F; Piazzon F; Rohr F; van Spronsen FJ; Vargas P; Wilcox G; Bhattacharya K
    Mol Genet Metab; 2019 May; 127(1):1-11. PubMed ID: 31103398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations.
    Pey AL; Pérez B; Desviat LR; Martínez MA; Aguado C; Erlandsen H; Gámez A; Stevens RC; Thórólfsson M; Ugarte M; Martínez A
    Hum Mutat; 2004 Nov; 24(5):388-99. PubMed ID: 15459954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.
    Levy HL; Milanowski A; Chakrapani A; Cleary M; Lee P; Trefz FK; Whitley CB; Feillet F; Feigenbaum AS; Bebchuk JD; Christ-Schmidt H; Dorenbaum A;
    Lancet; 2007 Aug; 370(9586):504-10. PubMed ID: 17693179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.